Alapis: You know what the problem with our stock
Post# of 30028
Posted On: 09/05/2014 4:48:13 PM
Alapis: You know what the problem with our stock price is? Ignorance on the part of shareholders about how LymPro works and how it will be used by Research Companies doing AD clinical trials.
Seriously, with all due respect, you don't know what you're talking about with LymPro. Do you know why Gerald spent 10 minutes during the CC getting into the univariant biomarkers and how they will be used by Research companies verses LymPro's multivariant biomarker capabilities?
All of us are focused on the multivariant sens & spec numbers in the 90s and when the July Conferences gave us univariant data in the 70s and 80s - the scientists all dropped their jaws and the ignorant shareholder had to change their underwear!! We dropped by 45% because of Money Runner manipulation and shareholder ignorance on the LymPro data given.
What Gerald told us is that the Pharmas doing AD clinical trials were very impressed with the 80% accuracy of our CD 19 univariant bio-marker in LymPro. What Gerald heard from them is they like how easy it is to just run a single "stand alone" univariant biomarker like CD 19 versus doing all 6 biomarkers and then doing complex math formulas to achieve multivariant accuracy in the 90s. The 80% accuracy is as good or better than the accuracy of what they're using now, and it will save them 30 to 40% to use CD 19!!! So they are ready to go and use it right away as a companion diagnostic with the screening test they are using now.
You are wrong about LymPro not generating revenue. It will start slow in January 2015, be moderate by summer, and outrageous by year end! Wall Street loves small little companies that start generating strong revenue. Lympro will be a very strong revenue generator.
Seriously, with all due respect, you don't know what you're talking about with LymPro. Do you know why Gerald spent 10 minutes during the CC getting into the univariant biomarkers and how they will be used by Research companies verses LymPro's multivariant biomarker capabilities?
All of us are focused on the multivariant sens & spec numbers in the 90s and when the July Conferences gave us univariant data in the 70s and 80s - the scientists all dropped their jaws and the ignorant shareholder had to change their underwear!! We dropped by 45% because of Money Runner manipulation and shareholder ignorance on the LymPro data given.
What Gerald told us is that the Pharmas doing AD clinical trials were very impressed with the 80% accuracy of our CD 19 univariant bio-marker in LymPro. What Gerald heard from them is they like how easy it is to just run a single "stand alone" univariant biomarker like CD 19 versus doing all 6 biomarkers and then doing complex math formulas to achieve multivariant accuracy in the 90s. The 80% accuracy is as good or better than the accuracy of what they're using now, and it will save them 30 to 40% to use CD 19!!! So they are ready to go and use it right away as a companion diagnostic with the screening test they are using now.
You are wrong about LymPro not generating revenue. It will start slow in January 2015, be moderate by summer, and outrageous by year end! Wall Street loves small little companies that start generating strong revenue. Lympro will be a very strong revenue generator.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼